Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa Bay news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Charlotte news in your inbox

Catch up on the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Test tubes in a lab at the National Cancer Institute at the National Institutes of Health. (Photo: Saul Loeb/AFP/Getty Images)

The Trump administration proposed bumping up hospital payments for CAR-T cancer therapy last week, but the question of how to pay for these procedures — which are individualized for each patient — is far from settled.

The big picture: Hospitals don't want to keep losing money over this treatment, and that could affect who gets it. More CAR-T therapies are in the development pipeline, but competition isn't a sure-fire solution given its personalized nature.

Hospitals can lose upwards of $100,000 dollars when they provide CAR-T therapy to a Medicare beneficiary on an inpatient basis.

  • That's because the procedure — which is offered by 2 manufacturers — has a price tag of about $373,000 per patient.
  • Medicare only reimburses for a portion of this cost when the procedure is done on an impatient basis, and while Medicare has proposed an increase to that amount for 2020, hospitals still won't be made whole.
  • The American Hospital Association said that the proposal "is not a permanent solution, [but] it will help in the short-term."
  • “Rather than dealing with price itself, we’ve just let the higher-than-we-want prices bleed into other parts of the health system," Memorial Sloan-Kettering Cancer Center's Peter Bach said.

If Medicare raises its reimbursement rate to make hospitals whole, that's expensive for taxpayers. But manufacturers aren't budging on their prices.

  • And even though experts say some hospitals might stop providing CAR-T if they continue to lose money, they also say it won't be enough hospitals to prompt manufacturers to lower their prices as a way to restore those lost sales.
  • “To the extent that [the manufacturers are] just saying that’s the price, take it or leave it…hospitals may not have the opportunity to negotiate," said Vanderbilt's Stacie Dusetzina. "It’s almost like you'd need a coordinated purchasing of CAR-T to be able to get that negotiating power. And I don’t think they have that right now."

Between the lines: The problem isn't as acute within the commercial market or when hospitals treat Medicare patients on an outpatient basis, which has a different payment structure.

  • People often need to be hospitalized because of complications associated with the treatment, meaning outpatient treatment isn't an option for everyone.
  • The fact that hospitals are losing money "does make it a question of whether or not it’s viable to keep treating people," Dusetzina said.
  • "Some hospitals just aren’t going to pay this…and that’s counter to the general objective, I think, of having new innovative treatments, which is that they get to patients," Bach added.

What we're watching: There are more CAR-T therapies in the development pipeline. If they make it to market, they'll be available for more uses.

  • “I think you’re going to see more improvements on process and technology, but the question is, what does this do on the price side?” said Ted Okon, executive director of the Community Oncology Alliance. "The cost should come down with increasing technological evolution and also with increased competition.”

The bottom line: Unless and until competition drives down the cost of CAR-T, or either Medicare or manufacturers cave, the system is at a standoff — one that isn't sustainable in the long run.

  • “Do we change our system to accommodate these treatments, because they are high value, or do we get to this impasse where we require them to come down on the price to make sure they’re adopted?” Dusetzina said.

Go deeper

Updated 19 mins ago - Economy & Business

2020 was the economy's worst year since 1946

Source: FRED; Billions of chained 2012 dollars; Chart: Axios Visuals

One of the last major economic report cards of the Trump era lends perspective to the historic damage caused by the pandemic, which continued to weigh on growth in the final quarter of 2020.

By the numbers: The U.S. economy grew at a 4% annualized pace in the fourth quarter, a sharp slowdown in growth compared to the prior quarter. For the full year, the economy shrank by 3.5% — the first annual contraction since the financial crisis and the worst decline since 1946.

Dion Rabouin, author of Markets
2 hours ago - Economy & Business

How GameStop exposed the market

Illustration: Eniola Odetunde/Axios

Retail traders have found a cheat code for the stock market, and barring some major action from regulatory authorities or a massive turn in their favored companies, they're going to keep using it to score "tendies" and turn Wall Street on its head.

What's happening: The share prices of companies like GameStop are rocketing higher, based largely on the social media organizing of a 3-million strong group of Redditors who are eagerly piling into companies that big hedge funds are short selling, or betting will fall in price.

Caitlin Owens, author of Vitals
3 hours ago - Health

Who benefits from Biden's move to reopen ACA enrollment

Photo: Chip Somodevilla/Getty Images

Nearly 15 million Americans who are currently uninsured are eligible for coverage on the Affordable Care Act marketplaces, and more than half of them would qualify for subsidies, according to a new Kaiser Family Foundation brief.

Why it matters: President Biden is expected to announce today that he'll be reopening the marketplaces for a special enrollment period from Feb. 15 to May 15, but getting a significant number of people to sign up for coverage will likely require targeted outreach.